EMA Authorised: Advate (octocog alfa) — Takeda Manufacturing Austria AG

View source ↗

Summary

The EMA authorised Advate (octocog alfa) by Takeda Manufacturing Austria AG for Hemophilia A, with a decision dated 21 May 2025.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemophilia

Drugs mentioned

• ADVATE (antihemophilic factor VIII)

Snippet

Status: Authorised. Therapeutic area: Hemophilia A. MAH: Takeda Manufacturing Austria AG. Decision date: 21/05/2025